# A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma

> **NCT00747123** · PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 30 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** ACE-011
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00747123
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09-01
- **Primary completion:** 2009-08-01
- **Final completion:** 2009-08-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00747123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00747123, "A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00747123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*